Search research articles
Contact Us
Filters
Showing results (1-10 of 16) with videos related to
Page
of 2
Sort By:
Bulletin Du Cancer
|
September 11, 2024
[Auto-inflammatory reaction triggered by Nivolumab: A case of adult-onset Still's disease-like syndrome]
Stéphanie Hermabessière, Pascale Palassin, Xavier Quantin, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 22, 2023
Immune checkpoint inhibitor-associated myocarditis and coronary artery disease: There may be more than meets the eye!
Alexandre T J Maria, Clement Delmas, Cyrille Coustal, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
May 24, 2016
Reply
Alexandre T J Maria, Christian Jorgensen, Alain Le Quellec, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 31, 2021
Rare cutaneous toxicity of immune checkpoint inhibitors: A case of durvalumab-induced dermatomyositis
Cyrille Coustal, Aurélie Du Thanh, François Roubille, et al.
Clinical Reviews in Allergy & Immunology
|
May 22, 2016
Adipose-Derived Mesenchymal Stem Cells in Autoimmune Disorders: State of the Art and Perspectives for Systemic Sclerosis
Alexandre T J Maria, Marie Maumus, Alain Le Quellec, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 1, 2022
Underreporting of Major Cardiac Adverse Events With Immune Checkpoint Inhibitors in Clinical Trials: Importance of Postmarketing Pharmacovigilance Surveys
Pascale Palassin, Jean-Luc Faillie, Cyrille Coustal, et al.
Journal of Autoimmunity
|
April 8, 2016
Human adipose mesenchymal stem cells as potent anti-fibrosis therapy for systemic sclerosis
Alexandre T J Maria, Karine Toupet, Marie Maumus, et al.
Frontiers in Immunology
|
September 19, 2017
Serum-Mediated Oxidative Stress from Systemic Sclerosis Patients Affects Mesenchymal Stem Cell Function
Guillaume Fonteneau, Claire Bony, Radjiv Goulabchand, et al.
Frontiers in Immunology
|
November 21, 2018
Fibrosis Development in HOCl-Induced Systemic Sclerosis: A Multistage Process Hampered by Mesenchymal Stem Cells
Alexandre T J Maria, Karine Toupet, Marie Maumus, et al.
Frontiers in Immunology
|
January 10, 2019
iNOS Activity Is Required for the Therapeutic Effect of Mesenchymal Stem Cells in Experimental Systemic Sclerosis
Alexandre T J Maria, Pauline Rozier, Guillaume Fonteneau, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 16) with videos related to
Sort By:
Page
of 2
Bulletin Du Cancer
|
September 11, 2024
[Auto-inflammatory reaction triggered by Nivolumab: A case of adult-onset Still's disease-like syndrome]
Stéphanie Hermabessière, Pascale Palassin, Xavier Quantin, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 22, 2023
Immune checkpoint inhibitor-associated myocarditis and coronary artery disease: There may be more than meets the eye!
Alexandre T J Maria, Clement Delmas, Cyrille Coustal, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
May 24, 2016
Reply
Alexandre T J Maria, Christian Jorgensen, Alain Le Quellec, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 31, 2021
Rare cutaneous toxicity of immune checkpoint inhibitors: A case of durvalumab-induced dermatomyositis
Cyrille Coustal, Aurélie Du Thanh, François Roubille, et al.
Clinical Reviews in Allergy & Immunology
|
May 22, 2016
Adipose-Derived Mesenchymal Stem Cells in Autoimmune Disorders: State of the Art and Perspectives for Systemic Sclerosis
Alexandre T J Maria, Marie Maumus, Alain Le Quellec, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 1, 2022
Underreporting of Major Cardiac Adverse Events With Immune Checkpoint Inhibitors in Clinical Trials: Importance of Postmarketing Pharmacovigilance Surveys
Pascale Palassin, Jean-Luc Faillie, Cyrille Coustal, et al.
Journal of Autoimmunity
|
April 8, 2016
Human adipose mesenchymal stem cells as potent anti-fibrosis therapy for systemic sclerosis
Alexandre T J Maria, Karine Toupet, Marie Maumus, et al.
Frontiers in Immunology
|
September 19, 2017
Serum-Mediated Oxidative Stress from Systemic Sclerosis Patients Affects Mesenchymal Stem Cell Function
Guillaume Fonteneau, Claire Bony, Radjiv Goulabchand, et al.
Frontiers in Immunology
|
November 21, 2018
Fibrosis Development in HOCl-Induced Systemic Sclerosis: A Multistage Process Hampered by Mesenchymal Stem Cells
Alexandre T J Maria, Karine Toupet, Marie Maumus, et al.
Frontiers in Immunology
|
January 10, 2019
iNOS Activity Is Required for the Therapeutic Effect of Mesenchymal Stem Cells in Experimental Systemic Sclerosis
Alexandre T J Maria, Pauline Rozier, Guillaume Fonteneau, et al.
Page
of 2